This company listing is no longer active
ImmuPharma Past Earnings Performance
Past criteria checks 0/6
Key information
-6.0%
Earnings growth rate
8.2%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | -15.5% |
Return on equity | -185.2% |
Net Margin | -6,906.6% |
Last Earnings Update | 31 Dec 2021 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How ImmuPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 21 | 0 | -8 | 2 | 4 |
30 Sep 21 | 0 | -8 | 2 | 3 |
30 Jun 21 | 0 | -8 | 3 | 3 |
31 Mar 21 | 0 | -7 | 3 | 3 |
31 Dec 20 | 0 | -7 | 3 | 2 |
30 Sep 20 | 0 | -6 | 4 | 2 |
30 Jun 20 | 0 | -5 | 4 | 2 |
31 Mar 20 | 0 | -6 | 4 | 2 |
31 Dec 19 | 0 | -6 | 4 | 3 |
30 Sep 19 | 0 | -7 | 4 | 3 |
30 Jun 19 | 0 | -7 | 4 | 4 |
31 Mar 19 | 0 | -7 | 4 | 4 |
31 Dec 18 | 0 | -7 | 3 | 5 |
30 Sep 18 | 0 | -7 | 3 | 5 |
30 Jun 18 | 0 | -7 | 3 | 5 |
31 Mar 18 | 0 | -7 | 3 | 5 |
31 Dec 17 | 0 | -6 | 2 | 5 |
30 Sep 17 | 0 | -5 | 2 | 5 |
30 Jun 17 | 0 | -5 | 2 | 5 |
31 Mar 17 | 0 | -5 | 2 | 5 |
31 Dec 16 | 0 | -5 | 1 | 5 |
30 Sep 16 | 0 | -6 | 2 | 5 |
30 Jun 16 | 0 | -6 | 2 | 5 |
31 Mar 16 | 0 | -5 | 2 | 4 |
31 Dec 15 | 0 | -4 | 2 | 3 |
30 Sep 15 | 0 | -3 | 1 | 3 |
Quality Earnings: IMMP.F is currently unprofitable.
Growing Profit Margin: IMMP.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMMP.F is unprofitable, and losses have increased over the past 5 years at a rate of 6% per year.
Accelerating Growth: Unable to compare IMMP.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMMP.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.9%).
Return on Equity
High ROE: IMMP.F has a negative Return on Equity (-185.2%), as it is currently unprofitable.